Every news story across policy, business, industry, and culture.
The DEA's marijuana rescheduling hearing begins June 29, 2026. Supporters like NORML and opponents like SAM have filed to participate. Here's what's at stake.
The DOJ moved state-licensed medical cannabis to Schedule III and the DEA set a June 29 rescheduling hearing. Here's what it means for taxes, operators, and the market.
A New York court granted an injunction blocking OCM directives that threatened 150+ licensed dispensaries over a reinterpreted school-proximity rule. What it means.
A federal ban on intoxicating hemp-derived THC — delta-8, THCA flower, THC-P and more — takes full effect November 12, 2026. What's banned and who it hits.
Cannabis stocks in 2026: as 280E tax relief lands, major MSOs like Trulieve, Green Thumb, and Curaleaf could post normalized profits for the first time.
Five states could legalize cannabis in 2026: Florida, Hawaii, New Hampshire, Pennsylvania, and Virginia. A look at the expanding U.S. cannabis map and what it means.
New York's OCM opened applications for Cannabis Showcase Events, letting licensed dispensaries sell at pop-ups and farmers' markets. Here's how the rules work and why it matters.
New York's OCM is developing 200+ regulatory amendments and signaling tougher enforcement against the unlicensed market. What the overhaul means for operators and shoppers.
In 2026, flower and pre-rolls are the cannabis categories gaining dollar sales, as smoking stays the top method and convenience drives the pre-roll boom.
Craft concentrates are booming in 2026: solventless live rosin, ultra-pure diamonds, and terpene-rich sauces are redefining the high end of the cannabis market.
Federal rescheduling ends the punishing 280E tax for cannabis operators. Will the savings lower dispensary prices for consumers, or pad margins? A realistic look.
With cannabis rescheduling underway, attention turns to banking reform. Why access to banks remains a barrier and how the federal shift could finally move it.
New York surpassed 600 licensed dispensaries and $3.3 billion in cumulative cannabis sales, growing 73.8% year-over-year. A look at how the market turned around and what's next.
Dispensary operators say Times Square has become a 'cannabis destination,' drawing tourists and locals to licensed storefronts. What it signals about NYC's legal market.
Cannabis operators are posting record quarters as the industry shifts from expansion to discipline. A veteran's read on consolidation, new state markets, and what it means.
The cannabis pharmaceuticals market, valued at $4.7 billion in 2025, is projected to hit $111.1 billion by 2032. Why rescheduling and research are accelerating medical cannabis.
Low-dose THC beverages are among the fastest-growing cannabis products of 2026, with sales up to 112% year-over-year as consumers choose them over alcohol. Here's why.
More than one in three U.S. women now use cannabis, making women the majority of consumers. How the wellness-driven shift is reshaping products and dispensaries.